美国 · SEC FORM 4
Krystal Biotech, Inc.
KRYS · Nasdaq · CIK 0001711279 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
60 同一窗口内观察到的 Form 4 交易行
58 sales · 2 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot.—
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 3,475,527
- 上期报告
- 3,163,642
- 日均成交量
- 310,502
- 回补天数
- 11.2
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
本地 Form 4 历史中没有合资格的代码 P 股票买入。
Form 4 申报证据
174 transaction lines in the latest 365-day window; 629 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Krishnan Suma | 卖出 (S) | Common Stock | 25,000 | USD 359.32 | USD 8,982,990 | SEC 申报 ↗ |
| 2026-09-04 | Krishnan Krish S | 卖出 (S) | Common Stock | 25,000 | USD 359.32 | USD 8,983,085 | SEC 申报 ↗ |
| 2026-08-14 | ROSSI DINO A | 卖出 (S) | Common Stock | 25,000 | USD 329.12 | USD 8,227,934 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Krishnan Suma | 卖出 (S) | Common Stock | 25,000 | USD 359.32 | USD 8,982,990 | SEC 申报 ↗ |
| 2026-09-04 | Krishnan Krish S | 卖出 (S) | Common Stock | 25,000 | USD 359.32 | USD 8,983,085 | SEC 申报 ↗ |
| 2026-08-14 | ROSSI DINO A | 卖出 (S) | Common Stock | 25,000 | USD 329.12 | USD 8,227,934 | SEC 申报 ↗ |
| 2026-08-14 | ROSSI DINO A | 赠与 (G) | Common Stock | 3,691 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-25 | Thomas John Charles | 卖出 (S) | Common Stock | 1,000 | USD 347.27 | USD 347,270 | SEC 申报 ↗ |
| 2026-06-25 | Thomas John Charles | 期权行权/转换 (M) | Common Stock | 1,000 | USD 179.25 | USD 179,250 | SEC 申报 ↗ |
| 2026-06-04 | Krishnan Suma | 卖出 (S) | Common Stock | 25,000 | USD 308.12 | USD 7,702,883 | SEC 申报 ↗ |
| 2026-06-04 | Krishnan Krish S | 卖出 (S) | Common Stock | 25,000 | USD 308.12 | USD 7,703,028 | SEC 申报 ↗ |
| 2026-05-26 | Thomas John Charles | 卖出 (S) | Common Stock | 642 | USD 302.03 | USD 193,903 | SEC 申报 ↗ |
| 2026-03-04 | Krishnan Suma | 卖出 (S) | Common Stock | 25,000 | USD 263.21 | USD 6,580,268 | SEC 申报 ↗ |
| 2026-03-04 | Krishnan Krish S | 卖出 (S) | Common Stock | 25,000 | USD 263.17 | USD 6,579,175 | SEC 申报 ↗ |
| 2026-03-02 | ROMANO KATHRYN | 卖出 (S) | Common Stock | 750 | USD 267.60 | USD 200,700 | SEC 申报 ↗ |
| 2026-02-27 | ROMANO KATHRYN | 期权行权/转换 (M) | Common Stock | 8,050 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-27 | ROMANO KATHRYN | 代扣税 (F) | Common Stock | 3,502 | USD 275.64 | USD 965,291 | SEC 申报 ↗ |
| 2026-02-27 | Krishnan Suma | 期权行权/转换 (M) | Common Stock | 67,225 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-27 | Krishnan Suma | 代扣税 (F) | Common Stock | 30,584 | USD 275.64 | USD 8,430,174 | SEC 申报 ↗ |
| 2026-02-27 | Krishnan Krish S | 期权行权/转换 (M) | Common Stock | 67,225 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-27 | Krishnan Krish S | 代扣税 (F) | Common Stock | 30,584 | USD 275.64 | USD 8,430,174 | SEC 申报 ↗ |
| 2026-02-27 | JANNEY DANIEL | 卖出 (S) | Common Stock | 11,803 | USD 275.59 | USD 3,252,845 | SEC 申报 ↗ |
| 2026-02-26 | JANNEY DANIEL | 卖出 (S) | Common Stock | 7,741 | USD 275.63 | USD 2,133,686 | SEC 申报 ↗ |
| 2026-02-25 | JANNEY DANIEL | 卖出 (S) | Common Stock | 700 | USD 275.00 | USD 192,500 | SEC 申报 ↗ |
| 2026-02-24 | JANNEY DANIEL | 卖出 (S) | Common Stock | 51,720 | USD 267.27 | USD 13,823,273 | SEC 申报 ↗ |
| 2026-02-24 | JANNEY DANIEL | 期权行权/转换 (M) | Common Stock | 37,895 | USD 2.46 | USD 93,222 | SEC 申报 ↗ |
| 2026-02-19 | ROSSI DINO A | 卖出 (S) | Common Stock | 18,950 | USD 261.41 | USD 4,953,728 | SEC 申报 ↗ |
| 2026-02-19 | ROSSI DINO A | 期权行权/转换 (M) | Common Stock | 18,950 | USD 8.79 | USD 166,570 | SEC 申报 ↗ |
| 2026-02-09 | ROMANO KATHRYN | 卖出 (S) | Common Stock | 12,500 | USD 272.14 | USD 3,401,703 | SEC 申报 ↗ |
| 2026-02-09 | ROMANO KATHRYN | 期权行权/转换 (M) | Common Stock | 12,500 | USD 63.55 | USD 794,375 | SEC 申报 ↗ |
| 2026-02-09 | ROMANO KATHRYN | 赠与 (G) | Common Stock | 750 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-05 | Krishnan Suma | 赠与 (G) | Common Stock | 5,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-05 | Krishnan Krish S | 赠与 (G) | Common Stock | 5,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | KRYS |
| CIK | 0001711279 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 629 transaction lines from 2020-02-18 to 2026-09-04 0 P purchase lines · 510 S sale lines · 119 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.